infants

Merck’s ENFLONSIA (clesrovimab-cfor), a new monoclonal antibody for RSV prevention in infants under eight months, has received a positive recommendation from the CDC’s ACIP. Approved by the FDA, ENFLONSIA aims to protect against RSV lower respiratory tract disease, with ordering for the 2025-2026 season starting in July. The standardized dose provides rapid, lasting protection for a typical five-month RSV season, with potential accessibility via the Vaccines for Children Program.